by @dministrator | Jul 3, 2023 | NevakarInjectables
— Ready-to-dilute, multi-dose vials reduce compounding time and waste — Bridgewater, NJ, July 3, 2023 – Nevakar Injectables Inc. (“Nevakar”), a biopharmaceutical company developing multiple sterile injectable products for use in the critical and...
by @dministrator | May 2, 2022 | NevakarInjectables
Bridgewater, NJ, May 2, 2022 – Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings. Nevakar announced...
by @dministrator | Apr 28, 2022 | NevakarInjectables
Bridgewater, NJ, USA, April 28, 2022 – Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, and announced...
by @dministrator | Mar 28, 2022 | NevakarInjectables
Bridgewater, NJ, USA, March 28, 2022 – Nevakar Injectables Inc., a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, announced today the launch of its ready-to-use Ephedrine Sulfate...
by @dministrator | Mar 9, 2022 | NevakarInjectables
Bridgewater, NJ, USA, March 9, 2022 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has closed on $12 million in convertible notes with both existing and new investors....
by @dministrator | May 25, 2021 | NevakarInjectables
Bridgewater, NJ (May 25, 2021) – Nevakar Inc. (“Nevakar”), a privately held biopharmaceutical company, today announces the establishment of Nevakar Injectables Inc., a newly formed company with an established portfolio of products focused on critical patient care,...
Recent Comments